ORIENT BIO Inc. (002630.KS)
KRW 967.0
(-14.65%)
KRW 967.0
(-14.65%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 15.66 Billion KRW | -105.61% |
| 2022 | -6.1 Billion KRW | 307.17% |
| 2021 | 1.28 Billion KRW | -41.31% |
| 2020 | -13.63 Billion KRW | 160.49% |
| 2019 | -8.17 Billion KRW | -105.82% |
| 2018 | -1.66 Billion KRW | -295.63% |
| 2017 | -618 Million KRW | 88.5% |
| 2016 | -13.73 Billion KRW | -159.88% |
| 2015 | 6.15 Billion KRW | 5.17% |
| 2014 | 7.8 Billion KRW | 457.61% |
| 2013 | -2.26 Billion KRW | -80.41% |
| 2012 | 7.37 Billion KRW | 474.02% |
| 2011 | -5.31 Billion KRW | -274.94% |
| 2010 | 1.08 Billion KRW | 113.81% |
| 2009 | -5.97 Billion KRW | -237.93% |
| 2008 | 5.71 Billion KRW | -20.68% |
| 2007 | 7.18 Billion KRW | 110.86% |
| 2006 | 3.41 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 853.79 Million KRW | -152.39% |
| 2023 Q4 | -558.41 Million KRW | -209.23% |
| 2023 Q3 | 511.24 Million KRW | -58.27% |
| 2023 FY | - KRW | -105.61% |
| 2023 Q1 | 2.97 Billion KRW | 1235.32% |
| 2023 Q2 | 1.22 Billion KRW | -58.76% |
| 2022 Q2 | 1.04 Billion KRW | -81.55% |
| 2022 FY | - KRW | 307.17% |
| 2022 Q4 | -261.7 Million KRW | -200.52% |
| 2022 Q3 | 260.35 Million KRW | -75.17% |
| 2022 Q1 | 5.68 Billion KRW | 0.0% |
| 2021 Q3 | 2.05 Billion KRW | 119.64% |
| 2021 FY | - KRW | -41.31% |
| 2021 Q1 | 1.77 Billion KRW | 454.67% |
| 2021 Q2 | 934.53 Million KRW | -47.3% |
| 2020 Q4 | -500.01 Million KRW | -119.12% |
| 2020 FY | - KRW | 160.49% |
| 2020 Q1 | 198.2 Million KRW | 122.48% |
| 2020 Q2 | 715.49 Million KRW | 260.99% |
| 2020 Q3 | 2.61 Billion KRW | 265.58% |
| 2019 Q1 | -516.13 Million KRW | -139.68% |
| 2019 FY | - KRW | -105.82% |
| 2019 Q3 | 520.7 Million KRW | 109.0% |
| 2019 Q2 | -5.78 Billion KRW | -1020.85% |
| 2019 Q4 | -881.51 Million KRW | -269.29% |
| 2018 FY | - KRW | -295.63% |
| 2018 Q3 | -1.14 Billion KRW | -55.27% |
| 2018 Q4 | 1.3 Billion KRW | 214.03% |
| 2018 Q1 | 1.18 Billion KRW | 294.12% |
| 2018 Q2 | -734.73 Million KRW | -161.88% |
| 2017 FY | - KRW | 88.5% |
| 2017 Q2 | 618.92 Million KRW | 218.72% |
| 2017 Q3 | 1 Billion KRW | 63.17% |
| 2017 Q1 | -521.32 Million KRW | -256.7% |
| 2017 Q4 | -611.68 Million KRW | -160.57% |
| 2016 FY | - KRW | -159.88% |
| 2016 Q2 | -842.25 Million KRW | -12.63% |
| 2016 Q3 | -1.14 Billion KRW | -36.03% |
| 2016 Q4 | 332.67 Million KRW | 129.04% |
| 2016 Q1 | -747.82 Million KRW | -174.86% |
| 2015 Q1 | 1.71 Billion KRW | 92.11% |
| 2015 Q4 | 998.93 Million KRW | -52.51% |
| 2015 Q3 | 2.1 Billion KRW | 111.87% |
| 2015 FY | - KRW | 5.17% |
| 2015 Q2 | 992.78 Million KRW | -42.23% |
| 2014 Q3 | 1.66 Billion KRW | -17.03% |
| 2014 Q1 | 2.63 Billion KRW | 404.87% |
| 2014 FY | - KRW | 457.61% |
| 2014 Q2 | 2 Billion KRW | -23.83% |
| 2014 Q4 | 894.47 Million KRW | -46.22% |
| 2013 Q2 | -98.53 Million KRW | -109.9% |
| 2013 FY | - KRW | -80.41% |
| 2013 Q4 | -863.1 Million KRW | -142.72% |
| 2013 Q3 | 2.02 Billion KRW | 2150.32% |
| 2013 Q1 | 995.05 Million KRW | 113.46% |
| 2012 FY | - KRW | 474.02% |
| 2012 Q2 | 995.73 Million KRW | -58.61% |
| 2012 Q3 | 1.28 Billion KRW | 28.76% |
| 2012 Q4 | 466.16 Million KRW | -63.64% |
| 2012 Q1 | 2.4 Billion KRW | 0.0% |
| 2011 Q3 | 655.24 Million KRW | 106.66% |
| 2011 Q2 | -9.84 Billion KRW | -1463.33% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 Q1 | 721.87 Million KRW | 0.0% |
| 2011 FY | - KRW | -274.94% |
| 2010 Q4 | - KRW | -100.0% |
| 2010 Q1 | 1.28 Billion KRW | 0.0% |
| 2010 Q2 | -120.42 Million KRW | -109.4% |
| 2010 Q3 | 1.39 Billion KRW | 1256.62% |
| 2010 FY | - KRW | 113.81% |
| 2009 Q1 | 1.58 Billion KRW | 0.0% |
| 2009 Q2 | 4.05 Billion KRW | 155.71% |
| 2009 Q3 | 134.96 Million KRW | -96.67% |
| 2009 Q4 | - KRW | -100.0% |
| 2009 FY | - KRW | -237.93% |
| 2008 Q1 | 1.51 Billion KRW | 0.0% |
| 2008 Q3 | 936.92 Million KRW | -1.33% |
| 2008 Q4 | - KRW | -100.0% |
| 2008 FY | - KRW | -20.68% |
| 2008 Q2 | 949.51 Million KRW | -37.13% |
| 2007 Q4 | - KRW | -100.0% |
| 2007 FY | - KRW | 110.86% |
| 2007 Q1 | 964.13 Million KRW | 0.0% |
| 2007 Q3 | 1.46 Billion KRW | 297.93% |
| 2007 Q2 | -738.62 Million KRW | -176.61% |
| 2006 FY | - KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Green Cross Holdings Corporation | 66.84 Billion KRW | 76.561% |
| Green Cross Holdings Corporation | 109.81 Billion KRW | 85.733% |
| Pharmicell Co., Ltd. | 8.44 Billion KRW | -85.621% |
| Green Cross Corporation | 109.81 Billion KRW | 85.733% |
| GeneOne Life Science, Inc. | -63.69 Billion KRW | 124.596% |
| Celltrion, Inc. | 897.26 Billion KRW | 98.254% |
| Samsung Biologics Co.,Ltd. | 1603.46 Billion KRW | 99.023% |
| SK bioscience Co.,Ltd. | 22.77 Billion KRW | 31.215% |
| SK Biopharmaceuticals Co., Ltd. | -22.2 Billion KRW | 170.557% |
| Prestige BioPharma Limited | -31.04 Billion KRW | 150.461% |